Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...

Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

The Schwab dividend ETF is a solid pick, but some stocks might offer more upside. Philip Morris International is delivering ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

During the second quarter of 2025, the Company repurchased shares of its common stock and recorded the cost of the shares, or $1.070 billion, as Treasury Stock. As of June 30, 2025, $2.814 billion ...

Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to inve ...

President Donald Trump gestures on the day he signs an executive order on prescription drug pricing during a press conference ...

Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 milli ...

President Donald Trump said his administration would “deploy every tool” to get drug prices reduced from large pharmaceutical ...

President Donald Trump called out 17 Big Pharma CEOs over "exorbitant" drug pricing in individual letters sent out Thursday, ...